Evommune, Inc.

EVMN

Market cap $629M

PALO ALTO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share.

PALO ALTO, Calif. , Oct. 30, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that on October 17, 2025, it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock.

Evommune, Inc. is seeking to raise $100 million in an IPO to advance its pipeline of inflammatory disease treatments. EVMN's lead candidate, EVO756, is in Phase 2 trials for chronic spontaneous urticaria and atopic dermatitis, with initial efficacy results expected in 2026. The market for atopic dermatitis drugs is large and growing, but EVMN faces intense competition from major pharmaceutical companies and other biopharmas.